Dr Narcyz Ghinea

Postdoctoral Researcher
Sydney Health Ethics
School of Public Health


Map

Biographical details

Narcyz Ghinea's research focuses on the regulation and funding of biomedical innovation. In addressing these challenges Narcyz balances the analytical skills he developed as a mathematician and an ethicist, with the practical experiences he gained working in peak health administration organisations, and his experience with engaging stakeholders using participatory methods.

As a graduate, Narcyz developed predictive clinical decision support tools at the Department of Neurosurgery at Liverpool Hospital. In 2004 he was awarded a Phd scholarship to pursue this work by the Ingham Institute, but instead sought real-world experience of policy development and decision making processes. He worked in peak health administration institutions including the Clinical Governance Unit of the South Western Sydney Area Health Service, the Greater Metropolitan Clinical Taskforce,NSW Department of Health (now Ministry of Health), and the Clinical Excellence Commission. In these roles he led the implementation of the Collaborating Hospital Audit of Surgical Mortality program in a health service, lead the national Mediciation Safety Self-Assessment program, and was long-time secretariat for NSW's peak medication safety expert advisory committee.

In 2015 Narcyz returned to full-time research atSydney Health Ethics,working on an NHMRC project investigating access to innovative cancer medicines. He completed his doctorate in 2017, atSt Vincent's Clinical Schooland theAustralian Institute of Health Innovation, UNSW. His doctorate focused on how clinicians justify using unapproved medicines. In 2018, Narcyz began working on an NHMRC project investigating conflict of interest in biomedicine, and in 2019 began working with theSydney Law Schoolon a NHMRC project on the regulation of stem cell therapies.

To date, my research has been entirely funded by the National Health and Medical Research Council.

My work has been published in high-impact journals including first author articles in the Lancet and BMJ. For a current list of research articles and projects refer to my ResearchGate profile.

Research interests

My research explores the regulation and funding of biomedical innovation, and access to unapproved treatments.

Teaching and supervision

Medicines policy, economics and ethics (BETH5209) (unit coordinator with Wendy Lipworth).

Topic Leader for the Public Health Capstone (PUBH5034).

Current projects

Improving funding of high-cost cancer medicines in Australia (NHMRC Project Grant).

An empirical and normative critique of off-label prescribing (funded through the NHMRC Patient Safety Program Grant).

In the media

I have been interviewed about my research by the New York Times, Fairfax, Radio National News, ABC Radio, ABC News, and the Medical Observer. I also regularly write for the Conversation. Some recent pieces I've written or co-authored include:

Articles that I have recently been interviewed for and quoted in include:

  • Cousins S. The Tasmanian Hep C buyers' club. The New York Times, July 25, 2017.
  • Pain C. 'Dallas buyers club' for cancer drugs presents a dilemma for patients and doctors. Medical Observer, March 3, 2017.
  • Lee J. 'Hundreds of cancer drugs' to enter market in next five years: report. Sydney Morning Herald, April 4, 2016.

Selected publications

Download citations: PDF RTF Endnote

Book Chapters

  • Pace, J., Ghinea, N., Wiersma, M., Morrell, B., Kerridge, I., Lipworth, W. (2019). Clinical Quandaries Associated With Accelerated Access to Medicines. In Kathleen Montgomery and Wendy Lipworth (Eds.), Medical Professionals: Conflicts and Quandaries in Medical Practice, (pp. 48-66). New York, NY: Routledge. [More Information]
  • Ghinea, N., Kerridge, I., Lipworth, W. (2019). Off-Label Prescribing: The Borderlands Between Clinical Practice and Experimentation. In Kathleen Montgomery and Wendy Lipworth (Eds.), Medical Professionals: Conflicts and Quandaries in Medical Practice, (pp. 28-47). New York, NY: Routledge.

Journals

  • Lipworth, W., Kerridge, I., Ghinea, N., Zalcberg, J. (2019). Clearing the air: towards agreement about access to high cost cancer medicines. Annals of Oncology, 30(1), 143-146. [More Information]
  • Wiersma, M., Ghinea, N., Kerridge, I., Lipworth, W. (2019). �Treat them into the grave�: cancer physicians� attitudes towards the use of high-cost cancer medicines at the end of life. Sociology of Health & Illness, 41(2), 343-359. [More Information]
  • Pace, J., Ghinea, N., Kerridge, I., Lipworth, W. (2018). An ethical framework for the creation, governance and evaluation of accelerated access programs. Health Policy, 122(9), 984-990. [More Information]
  • Pace, J., Ghinea, N., Kerridge, I., Lipworth, W. (2017). Accelerated Access to Medicines: An Ethical Analysis. Therapeutic Innovation and Regulatory Science, 51(2), 157-163. [More Information]
  • Ghinea, N., Little, M., Lipworth, W. (2017). Access to High Cost Cancer Medicines Through the Lens of an Australian Senate Inquiry-Defining the "Goods" at Stake. Journal of Bioethical Inquiry, 14(3), 401-410. [More Information]
  • Pace, J., Ghinea, N., Kerridge, I., Lipworth, W. (2017). Caution needed in introduction of provisional approvals for medicines. Internal Medicine Journal, 47(11), 1321-1324. [More Information]
  • Ghinea, N., Kerridge, I., Little, M., Lipworth, W. (2017). Challenges to the validity of using medicine labels to categorize clinical behavior: An empirical and normative critique of "off-label" prescribing. Journal of Evaluation in Clinical Practice, 23(3), 574-581. [More Information]
  • Pace, J., Ghinea, N., Kerridge, I., Lipworth, W. (2017). Demands for access to new therapies: Are there alternatives to accelerated access? BMJ, 359, 1-4. [More Information]
  • Ghinea, N., Lipworth, W., Day, R., Hill, A., Dore, G., Danta, M. (2017). Importation of generic hepatitis C therapies: bridging the gap between price and access in high-income countries. The Lancet, 389(10075), 1268-1272. [More Information]
  • Danta, M., Ghinea, N. (2017). The complex legal and ethical issues related to generic medications. Viral hepatitis: a case study. Journal of Virus Eradication, 3(2), 77-81.
  • Harper, C., Ghinea, N., Lipworth, W. (2017). The Right to Health: Implications for the Funding of Medicines in Australia. Journal of Law and Medicine, 24(3), 640-655.
  • Ghinea, N., Lipworth, W. (2016). Affordable access to innovative cancer medicines - don't forget the prices. Medical Journal of Australia, 204(6), 214-215.e1. [More Information]
  • Lipworth, W., Ghinea, N., Kerridge, I. (2016). Negotiating limits to the funding of high cost cancer medicines. Cancer Forum, 40(2), 93-96.
  • Ghinea, N., Lipworth, W., Kerridge, I. (2016). Propaganda or the cost of innovation? Challenging the high price of new drugs. BMJ, 352, 1-4. [More Information]
  • Ghinea, N., Lipworth, W., Kerridge, I. (2015). Evidence, regulation and 'rational' prescribing: The case of gabapentin for neuropathic pain. Journal of Evaluation in Clinical Practice, 21(1), 28-33. [More Information]
  • Ghinea, N., Lipworth, W., Kerridge, I. (2015). Off-Label Promotion of Prescription Medicine: Is It Ever Justifiable? Therapeutic Innovation and Regulatory Science, 49(3), 359-363. [More Information]
  • Ghinea, N., Lipworth, W., Little, J., Kerridge, I., Day, R. (2015). Overcoming Entrenched Disagreements: the Case of Misoprostol for Post-Partum Haemorrhage. Developing World Bioethics, 15(1), 48-54. [More Information]
  • Day, R., Lipworth, W., Ghinea, N. (2015). The Ethics Around Drug Labels and Generic Medicines. Therapeutic Innovation and Regulatory Science, 49(3), 348-351. [More Information]
  • Ghinea, N., Lipworth, W., Kerridge, I., Little, J., Day, R. (2014). Ethics & Evidence in Medical Debates: The Case of Recombinant Activated Factor VII. The Hastings Center Report, 44(2), 38-45. [More Information]
  • Ghinea, N., Ghinea, N., Lipworth, W., Lipworth, W., Kerridge, I., Kerridge, I., Day, R., Day, R. (2012). No evidence or no alternative? Taking responsibility for off-label prescribing. Internal Medicine Journal, 42(3), 247-251. [More Information]

2019

  • Lipworth, W., Kerridge, I., Ghinea, N., Zalcberg, J. (2019). Clearing the air: towards agreement about access to high cost cancer medicines. Annals of Oncology, 30(1), 143-146. [More Information]
  • Pace, J., Ghinea, N., Wiersma, M., Morrell, B., Kerridge, I., Lipworth, W. (2019). Clinical Quandaries Associated With Accelerated Access to Medicines. In Kathleen Montgomery and Wendy Lipworth (Eds.), Medical Professionals: Conflicts and Quandaries in Medical Practice, (pp. 48-66). New York, NY: Routledge. [More Information]
  • Ghinea, N., Kerridge, I., Lipworth, W. (2019). Off-Label Prescribing: The Borderlands Between Clinical Practice and Experimentation. In Kathleen Montgomery and Wendy Lipworth (Eds.), Medical Professionals: Conflicts and Quandaries in Medical Practice, (pp. 28-47). New York, NY: Routledge.
  • Wiersma, M., Ghinea, N., Kerridge, I., Lipworth, W. (2019). �Treat them into the grave�: cancer physicians� attitudes towards the use of high-cost cancer medicines at the end of life. Sociology of Health & Illness, 41(2), 343-359. [More Information]

2018

  • Pace, J., Ghinea, N., Kerridge, I., Lipworth, W. (2018). An ethical framework for the creation, governance and evaluation of accelerated access programs. Health Policy, 122(9), 984-990. [More Information]

2017

  • Pace, J., Ghinea, N., Kerridge, I., Lipworth, W. (2017). Accelerated Access to Medicines: An Ethical Analysis. Therapeutic Innovation and Regulatory Science, 51(2), 157-163. [More Information]
  • Ghinea, N., Little, M., Lipworth, W. (2017). Access to High Cost Cancer Medicines Through the Lens of an Australian Senate Inquiry-Defining the "Goods" at Stake. Journal of Bioethical Inquiry, 14(3), 401-410. [More Information]
  • Pace, J., Ghinea, N., Kerridge, I., Lipworth, W. (2017). Caution needed in introduction of provisional approvals for medicines. Internal Medicine Journal, 47(11), 1321-1324. [More Information]
  • Ghinea, N., Kerridge, I., Little, M., Lipworth, W. (2017). Challenges to the validity of using medicine labels to categorize clinical behavior: An empirical and normative critique of "off-label" prescribing. Journal of Evaluation in Clinical Practice, 23(3), 574-581. [More Information]
  • Pace, J., Ghinea, N., Kerridge, I., Lipworth, W. (2017). Demands for access to new therapies: Are there alternatives to accelerated access? BMJ, 359, 1-4. [More Information]
  • Ghinea, N., Lipworth, W., Day, R., Hill, A., Dore, G., Danta, M. (2017). Importation of generic hepatitis C therapies: bridging the gap between price and access in high-income countries. The Lancet, 389(10075), 1268-1272. [More Information]
  • Danta, M., Ghinea, N. (2017). The complex legal and ethical issues related to generic medications. Viral hepatitis: a case study. Journal of Virus Eradication, 3(2), 77-81.
  • Harper, C., Ghinea, N., Lipworth, W. (2017). The Right to Health: Implications for the Funding of Medicines in Australia. Journal of Law and Medicine, 24(3), 640-655.

2016

  • Ghinea, N., Lipworth, W. (2016). Affordable access to innovative cancer medicines - don't forget the prices. Medical Journal of Australia, 204(6), 214-215.e1. [More Information]
  • Lipworth, W., Ghinea, N., Kerridge, I. (2016). Negotiating limits to the funding of high cost cancer medicines. Cancer Forum, 40(2), 93-96.
  • Ghinea, N., Lipworth, W., Kerridge, I. (2016). Propaganda or the cost of innovation? Challenging the high price of new drugs. BMJ, 352, 1-4. [More Information]

2015

  • Ghinea, N., Lipworth, W., Kerridge, I. (2015). Evidence, regulation and 'rational' prescribing: The case of gabapentin for neuropathic pain. Journal of Evaluation in Clinical Practice, 21(1), 28-33. [More Information]
  • Ghinea, N., Lipworth, W., Kerridge, I. (2015). Off-Label Promotion of Prescription Medicine: Is It Ever Justifiable? Therapeutic Innovation and Regulatory Science, 49(3), 359-363. [More Information]
  • Ghinea, N., Lipworth, W., Little, J., Kerridge, I., Day, R. (2015). Overcoming Entrenched Disagreements: the Case of Misoprostol for Post-Partum Haemorrhage. Developing World Bioethics, 15(1), 48-54. [More Information]
  • Day, R., Lipworth, W., Ghinea, N. (2015). The Ethics Around Drug Labels and Generic Medicines. Therapeutic Innovation and Regulatory Science, 49(3), 348-351. [More Information]

2014

  • Ghinea, N., Lipworth, W., Kerridge, I., Little, J., Day, R. (2014). Ethics & Evidence in Medical Debates: The Case of Recombinant Activated Factor VII. The Hastings Center Report, 44(2), 38-45. [More Information]

2012

  • Ghinea, N., Ghinea, N., Lipworth, W., Lipworth, W., Kerridge, I., Kerridge, I., Day, R., Day, R. (2012). No evidence or no alternative? Taking responsibility for off-label prescribing. Internal Medicine Journal, 42(3), 247-251. [More Information]

To update your profile click here. For support on your academic profile contact .